MTOR and Familial prostate cancer: Whilst preclinical studies and early phase clinical trials have demonstrated promise for combined PARP and PI3K–AKT–mTOR pathway blockade in patients with both HRR-proficient and -deficient cancers (determined by functional status of breast cancer susceptibility protein 1 and 2, BRCA1 and BRCA2) [337,338,339,340,341], it has not yet been explored in prostate cancer specifically.